[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-paroxysmal-or-persistent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-paroxysmal-or-persistent":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,70,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100535241","reversal-of-atrial-substrate-to-prevent-atrial-fibrillation-cohort-study-100535241",false,"NCT06249269","Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study","RASTA-Cohort","Inclusion Criteria:\n\n* symptomatic AF (CCS-SAF ≥2),\n* paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and either: i) BMI ≥ 30 or, ii) at least two of the following: BMI\\>27, BP\\>140\u002F90 mmHg or history of hypertension, Diabetes, Heart failure (prior heart failure admission or LVEF\\\u003C40%), Age ≥ 65 years, Prior stroke\u002FTIA, Current smoker, Excessive alcohol use {For women: 10 or more drinks\u002Fweek, more than 2 drinks a day (most days). For men: 15 or more drinks\u002Fweek, more than 3 drinks a day (most days)}, and iii) declined or were not approached for participation in the main study. Eligible patients must have received catheter ablation for AF during the same timeline of the RASTA-AF Mian Study (November 1st, 2019 to December 31st, 2025).\n\nExclusion Criteria:\n\n* permanent AF (AF lasting \\> 3 years),\n* prior catheter ablation for AF\n* New York Heart Association Class IV heart failure\n* participation in a cardiac rehabilitation program within the last year,\n* currently performing exercise training \\>150 minutes\u002Fweek of moderate to vigorous physical activity,\n* unable to exercise,\n* unable to give informed consent,\n* other noncardiovascular medical condition making 1 year survival unlikely\n* less than 18 years of age","ALL","18 Years",{"count":19,"type":20},198,"ESTIMATED","2 Years","OBSERVATIONAL","Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It results in high healthcare costs and significant morbidity, especially for patients with severe symptoms. The RASTA-AF randomized control trial (RCT) is designed to answer the following question: does vigorous treatment of AF with aggressive risk factor management plus catheter ablation reduce AF-related outcomes as compared to catheter ablation plus usual care in patients with symptomatic AF and risk factors that promote AF.\n\nThis study is a multicenter, prospective cohort study that will enrol patients who decline participation in the RASTA-AF RCT but agree to be followed in a registry. The objective of RASTA-Cohort is to determine whether patients who decline participation in the RASTA-AF RCT have different clinical characteristics and quality of life than patients who accept participation in the study, and whether they suffer from worse AF-related outcomes than patients in the RCT.",[25],"Atrial Fibrillation, Paroxysmal or Persistent","RECRUITING","2025-11-25",{"date":29,"type":30},"2025-12-02","ACTUAL",{"date":32,"type":30},"2024-05-01",{"date":34,"type":20},"2027-03",{"name":36,"class":37},"Ratika Parkash","OTHER",7,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100558937","safety-and-efficacy-of-the-coolcryo-system-for-cardiac-cryoablation-in-the-treatment-of-atrial-fibrillation-100558937","NCT06557616","Safety and Efficacy of the CoolCryo System for Cardiac Cryoablation in the Treatment of Atrial Fibrillation","Evaluation of the Safety and Efficacy of the CoolCryo System for Cardiac Cryoablation in the Treatment of Atrial Fibrillation in a Single-arm, Non-randomised, Open-label Clinical Trial","CoolCryo","Inclusion Criteria:\n\n1. Written consent from the patient to participate in the study.\n2. age ≥18 years.\n3. patient qualified for mitral valve surgery (mitral valve plication or mitral valve replacement \"with\" or \"without\" left atrial appendage closure).\n4. a documented diagnosis of co-occurrence of paroxysmal or persistent atrial fibrillation (AF) since at least 3 months prior to surgery with exclusion of acute conditions.\n\nExclusion Criteria:\n\n1. Lack of written consent from the patient to participate in the study.\n2. Failure to meet the inclusion criteria.\n3. Contraindications to the cryoablation procedure.\n4. Patient breastfeeding, pregnant or planning pregnancy within 6 months of study treatment.\n5. co-morbidities and\u002For conditions that may cause atrial fibrillation (uncompensated hyperthyroidism or hypothyroidism, acute infection, pheochromocytoma, significant dyselectrolitemia).\n6. significant calcification of the left atrium.\n7. Condition after previous cardiac surgery.\n8. significant left atrial enlargement (size greater than 10 cm on echocardiography in one of the projections performed). projection).\n9. the patient is currently a participant in another clinical trial.\n10. The patient is on active biological therapy.\n11. emergency surgery.\n12. Life expectancy \\\u003C12 months.\n13. Any circumstances that, in the opinion of the Investigator, may prevent the patient from participating in the study, limit the ability to perform the procedures outlined in the study protocol or place an unreasonable risk on the patient.",{"count":48,"type":20},20,"The study involves endocardial cryoablation of the left and\u002For right atrium of the heart using the CoolCryo system as an adjunct to mitral valve surgery, with the aim of eliminating atrial fibrillation (AF), which is a common sequelae of mitral valve defects and is associated with an increased risk of ischaemic stroke, heart failure and death.",[25,51],"Mitral Valve Disease",[53,54,55,56,57,58],"cryoablation","cardiac cryoablation","arrhythmia","atrial fibrillation","mitral valve","concomitant ablation","2025-09-19",{"date":61,"type":30},"2025-09-23",{"date":63,"type":30},"2024-07-03",{"date":65,"type":20},"2026-06-30",{"name":67,"class":68},"Medinice S.A.","INDUSTRY",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100580415","deep-sedation-in-catheter-ablation-of-atrial-fibrillation-100580415","NCT06836999","Deep Sedation in Catheter Ablation of Atrial Fibrillation","Using Deep Sedation vs. Conscious Sedation in Catheter Ablation in Patients With Atrial Fibrillation: Intraprocedural Management and Outcome Evaluation","PRIORI-AF","Inclusion Criteria:\n\n● Patients diagnosed with AF (paroxysmal, persistent, or long-standing) at 18-75 years old who are eligible for the CA procedure\n\nExclusion Criteria:\n\n* has received CA procedure for AF or atrial septal defect repair before enrollment\n* left atrial diameter (LAD) ≥55 mm or thrombosis in the left atrium;\n* eGFR\\\u003C30mL\u002Fmin\u002F1.73㎡\n* a history of cerebrovascular disease within the last three months (including stroke and transient ischemic attack \\[TIA\\])\n* acute or severe systemic infection\n* intolerant to sedation or with a history suggestive of sleep apnea\n* BMI \\> 35 kg\u002F㎡\n* has contraindications to procedural sedation or refused to participate in this trial\n* Congenital heart disease, thyroid dysfunction, severe hepatic insufficiency (Child-Pugh classification B-C), severe coagulation dysfunction (international normalized ratio (INR) \\> 1.5 or partial activated prothrombin time (APTT) prolonged by ≥ 10 seconds, or plasma prothrombin time (PT) prolonged by ≥ 3 seconds, or fibrinogen (Fib) ≤ 1.5 g\u002FL), or active bleeding\n* pregnant women, breastfeeding women or women who plan to become pregnant during the study period, those who have a positive pregnancy test result during the screening period\n* life expectancy \\\u003C 12 months\n* those who have participated in other clinical drug trials within 3 months prior to enrollment\n* those who are known to be allergic to any of the ingredients such as lidocaine, propofol, soybeans, peanuts, etc.\n* those who, in the judgment of the investigator, are not suitable for this clinical study (e.g., not in line with the treatment that the research participants the treatment, research participant compliance, etc.).","75 Years",{"count":80,"type":20},1334,"INTERVENTIONAL",[83],"NA","The current practice of anesthesia for atrial fibrillation catheter ablation （CA） procedure is inconsistent, including general anesthesia, deep sedation, and conscious sedation.Due to the nature of deep sedation, it has been continuously gaining its position as one of the crucial components in standard practices of atrial fibrillation ablation during the last decade. Currently, a considerable number of procedures have been done using conscious sedation. Previous studies explored the benefits obtained from the employment of deep sedation in AF ablation procedures, mainly focused on pain reduction and intra-procedural safety. However, the benefits on long-term rhythmic outcomes, peri-procedural safety as well as benefits on procedural parameters and peri-procedural experiences from patients\u002Fablators\u002Flab staff have yet not to be thoroughly studied. We plan to conduct a prospective, multicenter, randomized, controlled trial to evaluate the benefits of deep sedation in catheter ablation of paroxysmal and persistent AF in multiple prospective, i.e., quantified intraprocedural patients \u002F physicians \u002F lab staffs \u002F mapper clinical specialist experiences, and the procedure safety.",[86,25,87,88],"Atrial Fibrillation","Deep Sedations","Conscious Sedation",[90,91,92,56],"deep sedation","conscious sedation","catheter ablation","NOT_YET_RECRUITING","2025-02-27",{"date":96,"type":30},"2025-03-04",{"date":98,"type":20},"2025-03-03",{"date":100,"type":20},"2027-12-31",{"name":102,"class":37},"The First Affiliated Hospital of Dalian Medical University",16,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":81,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100500300","the-safe-prospective-registry-100500300","NCT05794464","The SAFE Prospective Registry","Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation\u002FElectrical Cardioversion","Inclusion Criteria:\n\n* Atrial fibrillation (Afib); (paroxysmal, persistent)\n* Patients indicated for catheter ablation and\u002For electrical cardioversion\n* Signed informed consent\n\nExclusion Criteria:\n\n* Longstanding or permanent atrial fibrillation\n* Severe mitral regurgitation\n* Heart failure with a permanently reduced ejection fraction\n* Cerebral ischaemic stroke in \\\u003C 3 months\n* Severe kidney injury\n* Severe renal insufficiency\n* Hepatic insufficiency limiting biomarker sampling\n* Myocardial infarction \\\u003C 3 months",{"count":112,"type":20},60,[83],"Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.",[25],[56,117,92,118],"secretoneurin","electrical cardio version","2023-09-06",{"date":121,"type":30},"2023-09-07",{"date":123,"type":30},"2023-05-01",{"date":125,"type":20},"2026-08",{"name":127,"class":37},"University Hospital Ostrava",1]